Tolvaptan is a vasopressin V2 receptor antagonist (vaptans) used in hyponatremia and ADPKD. In SIADH, why can tolvaptan cause rapid correction of sodium that risks osmotic demyelination syndrome (ODS)?

• A Blocking V2 receptors causes aquaresis (electrolyte-free water excretion) that can be very rapid and unpredictable, potentially raising serum sodium faster than 10–12 mEq/L in 24 hours — particularly in chronic hyponatremia where brain cells have adapted by extruding osmolytes ✓
• B Tolvaptan directly stimulates renal sodium reabsorption, adding sodium too quickly
• C Tolvaptan increases AVP secretion by feedback, causing paradoxical initial water retention before aquaresis
• D Tolvaptan inhibits aldosterone, causing sodium retention that is difficult to titrate

Explanation

In SIADH, the kidney retains free water due to inappropriate ADH action on V2 receptors in collecting duct principal cells. Tolvaptan blocks V2 receptors, preventing aquaporin-2 insertion into the collecting duct apical membrane — producing pure electrolyte-free water excretion (aquaresis) without sodium loss. This aquaresis can be rapid, unpredictable, and difficult to titrate, potentially raising serum sodium by more than 8–12 mEq/L per day. In chronic hyponatremia (>48 hours), neurons adapt by extruding organic osmolytes (myoinositol, taurine, glutamine). If sodium rises too rapidly, osmotic gradients pull water out of neurons before osmolytes can be replenished, causing osmotic demyelination (central pontine myelinolysis). Tolvaptan is therefore contraindicated in patients who cannot regulate water intake, and sodium correction rate must be carefully monitored.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.